Equities

Zentek Ltd

Zentek Ltd

Actions
  • Price (CAD)1.64
  • Today's Change0.04 / 2.50%
  • Shares traded38.30k
  • 1 Year change+7.19%
  • Beta0.9301
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company’s developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.

  • Revenue in CAD (TTM)39.36k
  • Net income in CAD-10.74m
  • Incorporated2008
  • Employees25.00
  • Location
    Zentek Ltd24 Corporate CtGUELPH N1G 5G5CanadaCAN
  • Phone+1 (705) 618-0900
  • Fax+1 (705) 618-0900
  • Websitehttps://www.zentek.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MustGrow Biologics Corp4.71m-423.96k91.37m0.00--25.36--19.39-0.0078-0.00780.09270.07260.9337--32.60---8.40-50.41-11.41-59.28-----9.00-298.734.84--0.1215--72,619.13372.5487.84------
Satellos Bioscience Inc0.00-28.53m91.84m12.00--4.46-----0.2528-0.25280.000.18160.00----0.00-78.28-107.22-85.23-136.58------------0.00-------40.33--459.46--
Oncolytics Biotech Inc0.00-27.64m105.54m29.00--11.66-----0.3644-0.36440.000.11750.00-------78.58-81.99-104.96-97.25------------0.1051-------11.75---40.52--
Medicenna Therapeutics Corp0.00-26.68m113.88m16.00--5.72-----0.3747-0.37470.000.26030.00----0.00-87.95-54.93-98.62-60.91-----------2.200.0087-------153.44------
Zentek Ltd39.36k-10.74m166.50m25.00--8.96--4,230.28-0.1062-0.10620.00040.17850.00160.22620.10591,574.40-44.08-47.65-48.37-51.12-1,038.69---27,288.92-13,980.331.63-140.860.0474---59.07--18.80---19.38--
Eupraxia Pharmaceuticals Inc0.00-39.52m168.49m29.00--12.67-----1.38-1.380.000.37340.00----0.00-162.00-127.84-261.49-935.99------------0.00-------52.63---7.69--
Cardiol Therapeutics Inc0.00-36.14m177.38m17.00--14.94-----0.5318-0.53180.000.14860.00-------119.31-58.97-158.53-68.62-------158,738.10----0.0157------9.06--36.06--
NervGen Pharma Corp0.00-24.01m177.88m10.00--19.35-----0.37-0.370.000.13080.00-------123.68-121.15-332.31-180.20-----------22.890.0139-------8.01--2.20--
Data as of Nov 22 2024. Currency figures normalised to Zentek Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.